ASX - By Stock
|
RDN |
Re:
Ann: Final Heritage Report Paves Path to Drilling at Andover
|
|
Banastas
|
107 |
59K |
20 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
107
|
59K
|
20
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Banastas
|
261 |
80K |
8 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
80K
|
8
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
Banastas
|
152 |
50K |
1 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
152
|
50K
|
1
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
Banastas
|
152 |
50K |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
152
|
50K
|
5
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Banastas
|
87 |
19K |
3 |
11/12/23 |
11/12/23 |
ASX - By Stock
|
87
|
19K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Banastas
|
87 |
19K |
3 |
11/12/23 |
11/12/23 |
ASX - By Stock
|
87
|
19K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: New Hires & Attendance at International MND Symposium
|
|
Banastas
|
56 |
14K |
4 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
56
|
14K
|
4
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: New Hires & Attendance at International MND Symposium
|
|
Banastas
|
56 |
14K |
3 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
56
|
14K
|
3
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
5 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
355
|
76K
|
5
|
|
ASX - By Stock
|
RDN |
Re:
Daily Discussion
|
|
Banastas
|
9.4K |
4.0M |
9 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
9.4K
|
4.0M
|
9
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
6 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
355
|
76K
|
6
|
|
ASX - By Stock
|
NUZ |
Re:
PHARMAUST MND UPDATE!!!!! Swallow and Walk!!!!
|
|
Banastas
|
40 |
9.4K |
2 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
40
|
9.4K
|
2
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
4 |
22/11/23 |
22/11/23 |
ASX - By Stock
|
355
|
76K
|
4
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Results of Annual General Meeting
|
|
Banastas
|
29 |
8.0K |
4 |
20/11/23 |
20/11/23 |
ASX - By Stock
|
29
|
8.0K
|
4
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Notice of Annual General Meeting & Proxy Form
|
|
Banastas
|
6 |
1.9K |
2 |
20/11/23 |
20/11/23 |
ASX - By Stock
|
6
|
1.9K
|
2
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
5 |
27/10/23 |
27/10/23 |
ASX - By Stock
|
355
|
76K
|
5
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
5 |
27/10/23 |
27/10/23 |
ASX - By Stock
|
355
|
76K
|
5
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
9 |
27/10/23 |
27/10/23 |
ASX - By Stock
|
355
|
76K
|
9
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
7 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
355
|
76K
|
7
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
7 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
355
|
76K
|
7
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
8 |
24/10/23 |
24/10/23 |
ASX - By Stock
|
355
|
76K
|
8
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
7 |
24/10/23 |
24/10/23 |
ASX - By Stock
|
355
|
76K
|
7
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
16 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
355
|
76K
|
16
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
5 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
355
|
76K
|
5
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
Banastas
|
355 |
76K |
11 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
355
|
76K
|
11
|
|
ASX - By Stock
|
RDN |
Re:
Ann: XRD confirms high Spodumene content at Andover South
|
|
Banastas
|
137 |
57K |
17 |
17/10/23 |
17/10/23 |
ASX - By Stock
|
137
|
57K
|
17
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Banastas
|
106 |
23K |
4 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
106
|
23K
|
4
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Banastas
|
106 |
23K |
3 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
106
|
23K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Banastas
|
106 |
23K |
3 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
106
|
23K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Banastas
|
106 |
23K |
2 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
106
|
23K
|
2
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Banastas
|
106 |
23K |
4 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
106
|
23K
|
4
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Banastas
|
106 |
23K |
3 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
106
|
23K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Who wants a Zoom Meeting with Management
|
|
Banastas
|
28 |
5.4K |
8 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
28
|
5.4K
|
8
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
Banastas
|
380 |
90K |
12 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
380
|
90K
|
12
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
Banastas
|
396 |
89K |
6 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
396
|
89K
|
6
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
Banastas
|
396 |
89K |
5 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
396
|
89K
|
5
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
Banastas
|
396 |
89K |
5 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
396
|
89K
|
5
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
Banastas
|
396 |
89K |
4 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
396
|
89K
|
4
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Motor Neurone Disease Phase 1/2 Clinical Trial Update
|
|
Banastas
|
165 |
37K |
20 |
11/07/23 |
11/07/23 |
ASX - By Stock
|
165
|
37K
|
20
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
Banastas
|
396 |
89K |
14 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
396
|
89K
|
14
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
Banastas
|
396 |
89K |
16 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
396
|
89K
|
16
|
|
ASX - By Stock
|
ECS |
Re:
Ann: Trading Halt
|
|
Banastas
|
37 |
9.4K |
3 |
23/06/23 |
23/06/23 |
ASX - By Stock
|
37
|
9.4K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust MND Trial Interim Analysis PK Outcomes
|
|
Banastas
|
105 |
28K |
4 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
105
|
28K
|
4
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Motor Neurone Disease Clinical Trial Update
|
|
Banastas
|
147 |
36K |
8 |
23/05/23 |
23/05/23 |
ASX - By Stock
|
147
|
36K
|
8
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: MPL has anti-cancer effects across multiple cancer types
|
|
Banastas
|
121 |
28K |
10 |
11/05/23 |
11/05/23 |
ASX - By Stock
|
121
|
28K
|
10
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
Banastas
|
56 |
15K |
9 |
29/04/23 |
29/04/23 |
ASX - By Stock
|
56
|
15K
|
9
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust launches international CEO search
|
|
Banastas
|
95 |
24K |
8 |
15/04/23 |
15/04/23 |
ASX - By Stock
|
95
|
24K
|
8
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: MND Trial Completes Enrolment of Cohort 2
|
|
Banastas
|
104 |
28K |
18 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
104
|
28K
|
18
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Canine Cancer Trial Update
|
|
Banastas
|
219 |
45K |
7 |
14/03/23 |
14/03/23 |
ASX - By Stock
|
219
|
45K
|
7
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Canine Cancer Trial Update
|
|
Banastas
|
219 |
45K |
5 |
14/03/23 |
14/03/23 |
ASX - By Stock
|
219
|
45K
|
5
|
|